Glomerular, Vascular, and Tubulo-Interstitial Diseases

  • Farahnak Assadi


The mother of a three-year old Asian boy with steroid-sensitive idiopathic nephrotic syndrome seeks advice regarding future therapy for her son. He has had four relapses of the nephrotic syndrome in the last year, each time responding rapidly to oral prednisone. Relapses have occurred when prednisone was tapered to <20 mg every other day. He now has reduced stature for his age and developed a behavioral disorder believed to be due to excess glucocorticoids. Another physician has advised the mother that a 10-week course of oral cyclophosphamide is essential to control her son’s disease and to prevent further relapses. The mother, however, is very fearful of the adverse side effects of cyclophosphamide.


Lupus Nephritis Renal Biopsy Membranous Nephropathy Pediatric Nephrology Minimal Change Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Durkan AM, Hodson EM, Willis NS, et al. (2001) Immunosuppressive agents in childhood nephritic syndrome: a meta-analysis of randomized controlled trials. Kidney Int 59:1919–1927CrossRefPubMedGoogle Scholar
  2. Staderrmann MB, Lilien MR, van der Kar, et al. (2003) Is renal biopsy required prior to cyclophosphamide use in steroid sensitive nephritic syndrome? Clin Nephrol 60:315–317Google Scholar
  3. Cohen AH, Adler SA (2001) Mesangial proliferative glomerulonephritis. In:Textbook of Nephrology, 4th ed., edited by Massry S and Glasscock RJ, Philadelphia, Lippincott, Williams and Wilkins, pp 717–719Google Scholar
  4. Hiraoka M, Tsukara H, Haruke S, et al. (2000) Older boys benefit from higher initial prednisone therapy for nephrotic syndrome. Kidney Int 58: 1247–1252CrossRefPubMedGoogle Scholar
  5. Levin AM (1999) Management of membranoproliferative glomerulonephritis: Evidence based recommendations. Kidney Int 55:S41–S46CrossRefGoogle Scholar
  6. Ponticelli C, Traversi L, Felicianmi A, et al. (2001) Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 60:1948–1954CrossRefPubMedGoogle Scholar
  7. Declaux C, Jacquot C, Callard P, et al. (1993) Acute reversible renal failure with macroscopic hematuria in IgA nephropathy. Nephrol Dial Transpl 8:199–199Google Scholar
  8. Kambham N, Markowitz GB, Valeri AM, et al. (2001) Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59:1498–1509CrossRefPubMedGoogle Scholar
  9. Matalon A, Valeri A, Appel GB (2000) Treatment of focal segmental glomerulosclerosis. Semin Nephrol 20:309–317PubMedGoogle Scholar
  10. Geddes CC, Cattran DC (2000) Treatment of idiopathic membranous nephropathy. Semin Nephrol 20:299–308PubMedGoogle Scholar
  11. Austin HA, Boumpas DT, Vaughan EM, et al. (1994) Predicting renal outcomes in severe lupus nephritis. Contributions of clinical and histological data. Kidney Int 43:544–550Google Scholar
  12. Illei GC, Austin HA, Crane M, et al. (2001) Combination therapy with pulse cyclophosphamide plus methylprednisolone improve long-term outcome without toxicity in patients with lupus nephritis. Ann Int Med 135 :248–257PubMedGoogle Scholar
  13. Ballardie FW, Roberts ISD (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142–148PubMedGoogle Scholar
  14. Levy J (2001) New aspects of management of ANCA-positive vasculitis. Nephrol Dial Transplant 16:1314–1317CrossRefPubMedGoogle Scholar
  15. Assadi F (2005) Value of urinary excretion of microalbuminuria in predicting glomerular lesions in children with isolated microscopic hematuria. Pediatr Nephrology 20:1131–1135CrossRefGoogle Scholar
  16. Monnens LAH (2001) Thin glomerular basement membrane disease. Kidney Int 60:799–800CrossRefPubMedGoogle Scholar
  17. Cattran DC (2001) Membranous nephropathy. In: Primer of kidney diseases National Kidney Foundation, edited by Greenberg AD, San Diego, Academic Press pp158–164Google Scholar
  18. Klotman PE (1999) HIV associated nephropathy. Kidney Int 56:1161–1176CrossRefPubMedGoogle Scholar
  19. Vanherweghem JL (2000) Nephropathy and herbal medicine. Am J Kidney Dis 35:330–332CrossRefPubMedGoogle Scholar
  20. Trejo O, Ramos-Casals M, Garcia-Carrasco J, et al. (2001) Cryoglobulinemia : study of etiologic factors, clinical and immunologic features in 443 patients from a single center. Medicine 80:252–262CrossRefPubMedGoogle Scholar
  21. Myllymaki J, Saha H, Mustonen J et al. (2003) IgM nephropathy: Clinical picture and long-term prognosis. Am J Kidney Dis 41:343–350CrossRefPubMedGoogle Scholar
  22. Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective study. Lancet 360:666–670CrossRefPubMedGoogle Scholar
  23. Nzerue CM, Hewan-Lowe K, Pierangeli S, et al. (2002) “Black swan in the kidney”: Renal involvement in the anti-phospholipid syndrome. Kidney Int 62:733–744CrossRefPubMedGoogle Scholar
  24. Gaskin G, Jayne DR (2002) The European Vasculitis Study Group: Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated vasculitis. J Am Soc Nephrol 13:S2A–S3AGoogle Scholar
  25. Jayne D (2002) Conventional treatment and outcome of Eegener’s granulomatosis. Cleveland Clinic J Med 69: S110–S115Google Scholar
  26. Gallagher H, Kwan JTC, Jayne DRW (2002) pulmonary-renal syndrome. A 4-yearr single center experience. Am J Kidney Dis 39:42–47CrossRefPubMedGoogle Scholar
  27. Nakao N, Yoshimura A, Morita H, et al. (2003) Combination of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor in non-diabetic renal disease (COOPERATE); A randomized clinical trial. Lancet 361:117–124CrossRefPubMedGoogle Scholar
  28. Van der Woude F (2002) Taking anti-neutrophil cytoplasmic antibody (ANCA) testing beyond the limits. Nephrol Dial Transplant 17:2081–2083CrossRefGoogle Scholar
  29. Han WK, Choi HK, Roth R, et al. (2003) Serila ANCA titers: Useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 63:1079–1085CrossRefPubMedGoogle Scholar
  30. Fontanellas A, Navarro S, Moran-Jiminez MJ, et al. (2002) Erythrocyte aminolevulinate dehydrase activity as lead marker in patients with chronic renal failure. Am J Kidney Dis 40:43–50CrossRefPubMedGoogle Scholar
  31. Dube GK, Markowitz GS, Radhakrishnan J, et al. (2002) Minimal change disease in SLE. Clin Nephrol 120:126–126Google Scholar
  32. Bazzi C, D’Amico G (2002) The urinary excretion of IgG and alpha-1 microglobulin predicts renal outcome and identifies patients deserving treatment in membranous nephropathy. Kidney Int 61:2276CrossRefPubMedGoogle Scholar
  33. Bazzi C, Petrini C, Rizza V, et al. (2001) Urinary excretion of IgG and alpha-1microglobulin predicts clinical course better than the extent of proteinuria in membranous nephropathy. Am J Kidney Dis 38:240–248CrossRefPubMedGoogle Scholar
  34. Schwartz MM, Korbet SM, Lewis EJ (2002) Immunotactoid glomerulopathy. J Am Soc Nephrol 13:1390–1397CrossRefPubMedGoogle Scholar
  35. Blume C, Ivens K, May P et al.. Fibrillary glomerulonephritis associated with crescents as a therapeutic challenge. Am J Kidney Dis 2002; 40:420–425CrossRefPubMedGoogle Scholar
  36. Korbet S (2002) Treatment of primary focal and segmental glomerulosclerosis. Kidney Int 62:2301–2310CrossRefPubMedGoogle Scholar
  37. Markowitz GS, Apple GB, Fine P, et al. (2001) Collapsing FSGS following treatment with high dose pamidronate. J Am Soc Nephrol 12:1164–1172PubMedGoogle Scholar
  38. Alper AB, Meleg-Smith S, Krane NK (2002) Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 40:1086–1090CrossRefPubMedGoogle Scholar
  39. Markowitz GS, Falkowitz DC, Isom R, et al. (2003) Membranous glomerulonephropathy and acute interstitial nephritis following treatment with celebrex. Clin Nephrol 59:137–143PubMedGoogle Scholar
  40. Staderrmann MB, Lilien MR, van der Kar, et al. (2003) Is renal biopsy required prior to cyclophosphamide use in steroid sensitive nephritic syndrome? Clin Nephrol 60:315–317Google Scholar
  41. Appel GA, Cook HT, Hageman G, et al. (2005) Membranoprolifertaive glomerulonephritis Type II (dense deposit disease): An update. J Am Soc Nephrol 16:1392–1403CrossRefPubMedGoogle Scholar
  42. Kashtan CE (2004) Familial hematuria due to Type IV collagen mutation: Alport syndrome and thin basement membrane nephropathy. Curr Opin Pediatr 16:177–181CrossRefPubMedGoogle Scholar
  43. Ballaride FW (2004) IgA nephropathy treatment 25 years on: can we halt progression? The evidence based. Nephrol Dial Transpl 19:1041–1046CrossRefGoogle Scholar
  44. Ballaride FW (2004) IgA nephropathy treatment 25 years on: can we halt progression? The evidence based. Nephrol Dial Transpl 19:1041–1046CrossRefGoogle Scholar
  45. Stippoli G, Manno C, Schena FP (2003) An evidence-based survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis 41:1129–1139CrossRefGoogle Scholar
  46. Sharman A, Furness P, Fehally J (2004) Distinguishing C1q nephropathy from lupus nephritis. Nephrol Dial Trasnpl 19:1420–1426CrossRefGoogle Scholar
  47. Panos J, Michelis MF, DeVita MV, et al. (2003) Combined converting enzyme inhibition and angiotensin receptor blockade reduces proteinuria greater than converting enzyme inhibitors alone: insight into mechanism. Clin Nephrol 60:13–21PubMedGoogle Scholar
  48. Booth AD, Pusey CD, Jayne DR (2004) Renal vasculitis: an update in 2004> Nephrol Dial Transplant 19:1964–1968CrossRefPubMedGoogle Scholar
  49. Klemmer PJ, Chalermskulrat W, Rief MS, et al. (2003) Plasmaphoresis therapy for diffuse alveolar hemorrhage in patients with small vessel vasculitis. Am J Kidney Dis 42:1149–1153CrossRefPubMedGoogle Scholar
  50. Jayne D, Rasmussen N, Andrassy H, et al. (2003) European vasculitis Study Group: A randomized trial of maintenance therapy for vasculitis associated with ANCA, N Engl J Med 349:36–44CrossRefPubMedGoogle Scholar
  51. Moroni G, Ventura D, Riva P, et al. (2004) Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 43:28–36CrossRefPubMedGoogle Scholar
  52. Coppo R, Bengoufa D, Veyradier A, et al. (2004) Severe ADAMTS-13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various auto-immune manifestations, lower platelet counts and mild renal impairment. Medicine 83:233–244CrossRefPubMedGoogle Scholar
  53. Caridi C, Bertelli R, Scolari F, et al. (2003) Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 14:1278–1286CrossRefPubMedGoogle Scholar
  54. Ruf RG, Lichtenberger A, Karle SM, et al. (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephritic syndrome. J Am Soc Nephrol 15:722–732CrossRefPubMedGoogle Scholar
  55. Weber S, Gribouval O, Esquivel EL, et al. (2004) NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephritic syndrome and low-transplant recurrence. Kidney Int 2004; 66:571–579CrossRefPubMedGoogle Scholar
  56. Ghiggeri G (2004) Recurrent focal glomerulosclerosis in the era of genetics and podocyte proteins: theory and therapy. Nephrol Dial Transplant 19:1036–1040CrossRefPubMedGoogle Scholar
  57. Huang K, Ferris ME, Andreoni KA (2004) The differential effect of race among pediatric kidney transplant recipients with FSGS. Am J Kidney Dis 43:1082–1090CrossRefPubMedGoogle Scholar
  58. Weening JJ, D’Agati VD, Schwartz MM, et al. (2004) for the ISN and Renal Pathology Society Working Group on the Classification of lupus Nephritis: The classification of glomerulonephritis in systemic lupus erythemarosus revisited. Kidney Int 65:521–530CrossRefPubMedGoogle Scholar
  59. Szczech LA, Gupta SK, Habash R, et al. (2004) The clinical epidemiology and course of the spectrum of renal disease associated with HIV infection. Kidney Int 66:1145–1152CrossRefPubMedGoogle Scholar
  60. Weiner NJ, Goodman JW, Kimmel PL (2003) The HIV-associated renal disease: current insight into pathogenesis and treatment. Kidney Int 63:1618–1631CrossRefPubMedGoogle Scholar
  61. Kasiske BL (1998) Hperlipidemia in patients with chronic kidney disease. Am J Kidney Dis 32 (suppl 3):S142–S156CrossRefPubMedGoogle Scholar
  62. Mann JF, Gerstein H, Pogue J, et al. (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134:629636Google Scholar
  63. Schwartz A, Krause PH, Kunzendrof U, et al. (2000) The outcome of acute interstitial nephritis: Risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 54:179–190Google Scholar
  64. Narla LD, Slovis TL, Watts FB, et al. (1988) The renal lesions of tuberosclerosis (cysts and angiomyolipoma)-secreening with sonography and computerized tomography. Pediatr Nephrol 18:205–209Google Scholar
  65. Saltel E, Angel JB, Futter NG, et al. (2000) Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol 164:1895–1897CrossRefPubMedGoogle Scholar
  66. Yoshikawa N, Lijima K, Ito H (1999) IgA nephropathy in children. Nephron 83:1–12CrossRefPubMedGoogle Scholar
  67. Madaio MP, Harrington JT (2001) The diagnosis of glomerular diseases: Acute glomerulonephritis and the nephritic syndrome. Arch Intern Med 161:25–34CrossRefPubMedGoogle Scholar
  68. Esson ML, Schrier RW (2002) Diagnosis and treatment of acute tubular necrosis. Ann Int Med 137:744–752PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Farahnak Assadi
    • 1
  1. 1.Rush University Medical CenterChicago

Personalised recommendations